Pet Noise Anxiety Market Size & Share 2026-2035

Pet Noise Anxiety Market Size

The pet noise anxiety market is projected to grow from USD 1.55 billion in 2026 to USD 2.74 billion by 2035, advancing at a 6.6% CAGR. The market covers products and services used to prevent, reduce, or manage fear responses to fireworks, thunderstorms, traffic, construction, alarms, and household noise in companion animals. It includes calming supplements and pheromones, pressure vests and wraps, prescription and veterinary-directed medications, sound therapy, behavioral tools, and connected monitoring products. It excludes general pet wellness products that do not have a noise-anxiety or behavioral-calming use case.

Noise sensitivity is commercially material because the event is acute, recurring, and visible to owners. Fireworks alone trigger significant fear responses in an estimated 39% of dogs, while untreated fear can translate into avoidance, escape attempts, destructive behavior, and wider anxiety patterns.^{[1]Tami, G., and Gallagher, A., *Description of the Behaviour of Domestic Dog (Canis Lupus Familiaris) by Experienced and Inexperienced People*, nature.com} The addressable need therefore spans an emergency purchase before a predictable event and a recurring management protocol that may combine training, a consumable product, and veterinary care.

The forecast captures an unusually broad price ladder. Average listed prices are approximately USD 23.99 for pheromone products, USD 31.67 for supplements, USD 38.98 for pressure vests, and USD 1.15 per prescription tablet. The medication figure understates the total treatment cost because a prescription episode can include consultation, dosing, and repeat-event use. Commercially, this range lets brands capture trial demand at lower price points while retaining premium tiers for clinically positioned, multi-ingredient, reusable, or veterinary-recommended offerings.

Key Drivers

Rising companion-animal ownership and pet-health spending

The pet-spending base provides the commercial capacity for behavioral-health categories. U.S. pet owners spent more than USD 158 billion on pet-related products and services in 2024, while approximately 45% of U.S. households own at least one dog.^{[2]American Pet Products Association, *APPA National Pet Owners Survey 2023–2024*, americanpetproducts.org} For manufacturers, the implication is not that every household becomes a treatment buyer. It is that a large installed base can be activated around predictable trigger events, with veterinary and retail education determining conversion.

Urban exposure to traffic, construction, alarms, and event noise

Urbanization expands exposure frequency rather than merely increasing pet numbers. The World Bank projects that 68% of the global population will live in urban areas by 2050, compared with approximately 57% in 2025.^{[4]World Bank, *Urban Development Overview and Urban Population Data*, worldbank.org} Dense housing, construction, traffic, and public celebrations make avoidance less practical. This favors products that can be used before an event, at home, and without a clinic visit.

Veterinary recognition of noise aversion as a treatable condition

Veterinary recognition changes category economics. A clinician’s recommendation can move an owner from a low-cost, self-selected chew to a protocol involving pheromone support, behavior modification, and prescription medication where appropriate. That recommendation function also supports repeat purchasing, particularly in categories where product response must be assessed over multiple events.

Product and regulatory advancement

Regulatory and product advances enlarge the credible treatment set. FDA-regulated dexmedetomidine products, NASC quality-seal programs for supplements, and established pheromone platforms give retailers and clinicians differentiated evidence narratives.^{[5]U.S. Food and Drug Administration, *Sileo (Dexmedetomidine Oromucosal Gel) New Animal Drug Application*, fda.gov} The resulting market advantage belongs to companies able to explain indication, administration, and limitations without implying that all calming products carry identical clinical support.

Key Restraints

Absence of standardized, broadly adopted treatment protocols

The category’s fragmented evidence base complicates choice. Owners may encounter prescription pharmaceuticals, homeopathic products, supplements, pheromones, pressure tools, and training advice in the same search journey, yet these options have different regulatory status and clinical support. This creates a commercial penalty for brands that rely on vague anxiety claims, because the owner still needs an understandable reason to choose a format and a threshold for seeking veterinary assistance.

Low diagnosis and treatment awareness outside dogs

Non-dog demand is underdeveloped partly because symptoms are less visible. Cats may hide or reduce activity, while birds and rabbits may show species-specific fear responses that owners do not immediately connect to noise. The constraint also creates an opportunity: cat-specific and avian formulations can grow from a lower base if products use administration formats and education designed for those species.

Pet Noise Anxiety Market Segment Analysis

By Animal

Dogs segment generated USD 861.9 million in 2025 of global revenue. Their leadership reflects both high observed incidence and the breadth of available interventions: Sileo and anticipated Tessie prescriptions, Ceva’s Adaptil, Thundershirt pressure wraps, Nutramax Solliquin, VetriScience Composure, and PetHonesty calming products all target the canine owner. Firework fear alone affects a large segment of the population. Owners can also observe bolting, vocalization, destructive behavior, and escape attempts more readily than many feline symptoms, which shortens the path from symptom recognition to purchase. The segment’s value is therefore driven by both prevalence and fast conversion.

The commercial implication is that dogs anchor the category’s cross-selling architecture. A veterinary clinic can recommend behavioral conditioning alongside a pheromone, a pressure vest, or medication for acute events. Online channels can replenish supplements and pheromone refills between seasonal peaks. Through 2035, canine revenue will remain the market’s volume base, but its share will be challenged at the margin as cat and other-animal offerings become more specific.

Cats form the second-largest animal category, although their responses often appear as withdrawal rather than outward agitation. Ceva’s Feliway Classic and Feliway Optimum use feline pheromone analogs, while Bonqat gives the U.S. market a prescription dexmedetomidine option distributed by Zoetis.^{[8]Ceva Sante Animale, *Adaptil and Feliway Clinical Evidence and Product Information*, ceva.com} PetHonesty, Nutravet, VetriScience, and Zylkene also support feline calming use cases. The segment’s current limitation is informational: a hidden or inactive cat can be misread as temperament rather than fear.

That behavior pattern changes product design requirements. Cat products benefit from easy administration, low handling stress, and a strong home-use proposition, making diffusers, palatable chews, and gel formats commercially relevant. The second-order effect is that a successful feline product can increase not only repeat purchases but also veterinary conversations about broader behavioral health. By 2030, feline growth will depend on whether manufacturers make indication and administration clearer than generic “calming” claims.

Other animals. Rabbits, birds, and horses remain smaller but strategically useful segments because product availability is scarce. Rabbits can experience acute sound-related stress, while fireworks can create safety risks for horses and handlers.^{[9]Marsbøll, A. F., and Manteca, X., *Review of Dog Stress and Fear Responses to Noise*, sciencedirect.com} NEKTON-Relax addresses birds facing loud-noise situations, including fireworks, with a formulation that includes chamomile, hops, valerian root, lavender, B vitamins, and L-tryptophan.^{[10]Jedds, *NEKTON-Relax Supplement: Noise and Anxiety Use Detail*, jedds.com} HomeoPet Thunder Anxiety also extends coverage beyond dog-only use cases.^{[11]HomeoPet, *Anxiety and Stress Product Range*, homeopet.com}

This segment is not a near-term revenue substitute for dogs. Its value lies in category extension: products designed for birds or multi-species households reduce dependence on the crowded canine supplement shelf. Retailers and specialist distributors can use these niche formats to differentiate assortment. Through 2035, other animals should contribute disproportionately to product innovation even if absolute revenue remains modest.

By Product Type

Calming products-supplements, pheromones, and other formats-are the largest product category and are projected to expand at a 6.6% CAGR. Supplements offer the broadest access and an average price of USD 31.67. Solliquin, Composure, Calming Bites, PetHonesty Hemp and Melatonin Calming products, Nutracalm, and Anxitane compete through ingredient composition, species positioning, and distribution. The NASC Quality Seal gives an important compliance signal in a lightly regulated supplement market.^{[7]National Animal Supplement Council, *NASC Quality Seal Program*, nasc.cc}

Pheromones occupy a more distinct evidence position. Adaptil and Feliway are sold as diffusers, collars, sprays, and wipes, making environmental treatment possible without direct administration. Pet Remedy offers a botanical alternative using valerian-root and nepetalactone-derived ingredients. CBD and hemp products add demand but also regulatory risk: the FDA has not formally approved CBD as an animal-health ingredient in the United States.^{[12]U.S. Food and Drug Administration, *FDA Regulation of Cannabis and Cannabis-Derived Compounds Including Cannabidiol*, fda.gov} The category’s commercial advantage is accessibility; its central challenge is making evidence and claims legible to consumers.

Pressure Vests and Wraps. Pressure vests use sustained torso compression as a non-drug calming mechanism. Thundershirt, commercialized by Ceva after its acquisition of Thundershirt International, is the leading platform. A study of pressure-vest use documented reductions in anxiety-associated behaviors in dogs.^{[13]King, C., et al., *A Noise Desensitization Trial in Dogs Using a Pressure Vest (Thundershirt)*, sciencedirect.com} At an average price of USD 38.98, the product is a mid-premium, reusable alternative to consumable formats.

The economic model differs from supplements. A vest has a higher upfront purchase but no automatic replenishment, so customer retention depends on adjacent products or repeat purchase across pets and sizes. International expansion and cat-specific development are more valuable growth levers than price escalation. The format will remain most relevant where owners prioritize a drug-free intervention before predictable events.

Medications. Medications address moderate-to-severe cases and carry the highest clinical differentiation. Orion’s dexmedetomidine oromucosal-gel platform underlies Sileo for dogs, Bonqat for cats, and Tessie for dogs; Zoetis holds exclusive U.S. marketing and distribution rights.^{[6]Zoetis, *Sileo and Bonqat Product Information*, zoetis.com} Sileo is FDA-cleared for canine noise aversion. Tessie’s FDA approval was anticipated for May 2026 and requires publication-status verification before external release.

Prescription access adds friction but also defensibility. Veterinary involvement protects clinical standards and makes the category less vulnerable to pure price competition. The unit price of approximately USD 1.15 per tablet does not describe the full care pathway, which can include consultation and event planning. Through 2035, medication growth will follow clinical adoption and availability rather than online merchandising alone.

Other Product Types. The remaining category includes training tools, desensitization audio, behavioral programs, connected stress monitors, and sound therapy. Pet Acoustics and RelaxoPet position sound systems as non-pharmacological options for dogs, cats, horses, birds, and other companion animals.^{[14]Pet Acoustics, *Product Overview and Research Background*, petacoustics.com[15]RelaxoPet, *Product Information and Technology Description*, relaxopet.com} Connected devices may detect physiological and behavioral signals, such as activity changes and elevated heart rate, before outward symptoms become severe.^{[16]American Veterinary Medical Association, *Emerging Technologies in Veterinary Practice*, avma.org}

This is the market’s most experimental segment. Its commercial promise comes from durable-device economics and data-enabled personalization, not from replacing medication or a veterinary diagnosis. By 2030, sound and monitoring products will be most successful when sold as part of a broader management protocol rather than as a stand-alone cure claim.

By Sales Channel

Offline channels held 63.6% of market revenue in 2025, or approximately USD 927.6 million. Veterinary clinics are the decisive access point for prescriptions and remain an influential recommendation channel for supplements and pheromones. Specialty retailers-including Petco and PetSmart in the United States, Pets at Home in the UK, and Fressnapf in Germany-provide merchandising breadth and advice-supported discovery. Clinics remain commercially important even when a product is later bought online, because initial veterinary endorsement reduces perceived product risk.

Offline leadership also reflects the category’s episodic urgency. An owner preparing for a storm or fireworks event may need product availability immediately. Inventory planning around New Year’s Eve, Fourth of July, thunderstorm season, Guy Fawkes Night, and local festivals can therefore materially affect conversion. The channel’s risk is that a narrow shelf can make ingredient-led supplements interchangeable unless staff education differentiates veterinary, pheromone, and pressure formats.

Online channels generated approximately USD 530.9 million in 2025, or 36.4% of global revenue. Amazon, Chewy, and Petco’s digital storefronts improve price discovery, assortment visibility, and recurring delivery for supplements and pheromone refills. Chewy AutoShip and comparable models are especially relevant because they can translate a seasonal trial into a replenishment routine. International platforms including Tmall, JD.com, Amazon India, Flipkart, and Mercado Libre extend access where veterinary or specialty-retail infrastructure is less developed.

The strategic question is not whether online displaces clinics. It is whether brands can preserve clinical trust after the first digital purchase. Product pages that explain trigger timing, species fit, administration, and escalation to a veterinarian should convert more effectively than broad wellness copy. Through 2035, online will gain share fastest in consumables, while prescription medicines will retain a clinic-centered pathway.

Pet Noise Anxiety Market Regional Analysis

North America

North America was the largest regional market in 2025, accounting for 46.7% of revenue, or USD 681.1 million. The region benefits from high pet-health spending, a developed veterinary network, broad specialty retail, and established regulatory pathways for animal drugs. U.S. pet spending exceeded USD 158 billion in 2024, and the dog-owning household base provides an unusually deep recurring demand pool.^{[3]American Veterinary Medical Association, *U.S. Pet Ownership Statistics*, avma.org} The U.S. market rose from USD 533.3 million in 2022 to USD 625.2 million in 2025, supported by prescription availability and premiumization.

Canada follows a similar but smaller pattern, with strong veterinary and specialty-retail access. The regional constraint is category fragmentation: abundant product choice can slow conversion when owners cannot distinguish evidence-backed interventions from broad calming claims. Tessie’s anticipated U.S. approval in May 2026 should be rechecked before publication; if confirmed, it will expand the Orion–Zoetis prescription platform for canine situational anxiety.

Europe

Europe generated USD 270.6 million in 2025, or 18.6% of global revenue. The region’s advantage comes from established behavioral-health suppliers: Ceva, Vetoquinol, Virbac, and Orion are rooted in France or Finland and hold deep veterinary-channel relationships. Germany’s large and diverse companion-animal population supports demand across dogs, cats, birds, and small pets.^{[17]Zentralverband Zoologischer Fachbetriebe, *Pet Population and Market Data, Germany*, zzf.de} The UK’s high online penetration contrasts with Southern European markets, where veterinary-clinic distribution remains more central.

The regional commercial implication is that European brands can compete on professional familiarity and evidence positioning, not simply consumer marketing. Domes Pharma’s December 2024 launch of Tessie and Bonqat in European markets widened the regional availability of Orion’s dexmedetomidine platform. Germany, the UK, France, Spain, Italy, and the Netherlands each support demand, but channel mix and language-specific product education constrain uniform execution.

Asia Pacific

Asia Pacific is projected to be the fastest-growing region at a 7.0% CAGR through 2035. Urbanization, rising disposable income, apartment-based pet ownership, and digital product discovery create favorable conditions in China, Japan, India, Australia, and South Korea. China is the largest regional market and benefits from recurring fireworks-related use cases around Chinese New Year. The China pet market exceeded RMB 200 billion in recent years, according to the China Pet Industry White Paper.^{[18]China Pet Industry Association / Pet Fair Asia, *China Pet Industry White Paper*, petfairasia.com}

Australia resembles North America and Europe in veterinary development and premium-wellness spending. India and South Korea are earlier-stage markets where online access can develop ahead of a dense specialty-retail footprint. Japan combines mature consumer expectations with sensitivity to product quality. The regional constraint is uneven clinical education and local availability, which makes portable, non-prescription formats more scalable than a uniform prescription-first strategy.

Latin America

Latin America remains emerging, with Brazil as the largest country opportunity. Brazil’s large companion-animal population and recurring high-noise celebrations create a clear usage case for supplements, pheromones, and behavior-management tools.^{[19]Instituto Pet Brasil, *Pet Industry Overview, Brazil*, institutopetbrasil.com} Mexico and Argentina add long-run potential but have lower per-capita pet-health spending and less developed organized distribution. The result is a price-sensitive market in which lower-cost products and online discovery may precede widespread veterinary behavioral specialization.

Middle East and Africa

The Middle East and Africa market is smaller but commercially selective. Saudi Arabia is an emerging opportunity as Vision 2030 quality-of-life initiatives and urban consumer growth broaden pet ownership and premium-service demand.^{[20]Saudi Vision 2030, *Quality of Life Program Overview*, vision2030.gov.sa} The UAE, particularly Dubai, serves as a regional retail and veterinary-services hub. South Africa anchors the African market through a comparatively developed veterinary profession and organized retail presence. The principal limitation is fragmented distribution across countries, which raises the value of regional partners and focused urban-market entry.

Pet Noise Anxiety Market Share & Competitive Landscape

The market is moderately concentrated. Ceva Sante Animale, Zoetis, Nestlé (Purina), Vetoquinol, and Virbac collectively accounted for approximately 40% of 2025 revenue, equivalent to roughly USD 583.4 million. Ceva leads non-pharmaceutical behavioral management through Adaptil, Feliway, and Thundershirt. Zoetis controls the U.S. commercial interface for Orion’s prescription dexmedetomidine products. Vetoquinol and Virbac bring veterinary-channel supplement credibility, while Purina contributes functional nutrition and broad retail reach.

North American competition is weighted toward Zoetis, Purina, and U.S.-centered supplement brands because prescription distribution and e-commerce are strong. Europe is more influenced by Ceva, Vetoquinol, Virbac, and Orion, reflecting established regional veterinary networks. Asia Pacific gives H&H Group-owned Zesty Paws an avenue to extend a U.S.-built digital brand through Asian distribution infrastructure. The competitive tension is between clinical validation, consumer-brand strength, and niche species or technology specialization.

Recent Industry Developments

Feb 2025: PetHonesty expanded its calming portfolio with a liquid supplement line, offering an administration option for pets that resist chews. The move broadens addressable use cases and reduces a common adherence barrier for supplement brands.

Dec 2025: Domes Pharma launched Tessie for dogs and Bonqat for cats in European markets. The launch extended the commercial footprint of Orion’s dexmedetomidine platform and widened veterinary choices for situational anxiety.